Rise and shine, folks. Another busy day is upon us. And it looks to be a hot one here at the Pharmalot campus, where the heat can be seen rising from the official mascot and the weeds are wilting before our eyes. Nonetheless, we shall persevere. And we hope that you will, as well. To increase your odds, why not join us for a cup of stimulation? We are quaffing cinnamon hazelnut this morning, for those who are interested. Meanwhile, here is your menu of tidbits. Stay cool and stay in touch. …
To the outside world and its countless health care customers, the data powerhouse IQVIA has portrayed itself as a bastion of privacy, fully committed to safeguarding the medical secrets it has spent decades collecting on tens of millions of Americans. But internal documents reveal a different reality. A STAT investigation found privacy lapses in the company’s secretive and long-running relationship with the credit-reporting firm Experian, whose detailed consumer data it buys and then links with Americans’ health records — all to deliver marketing insights to drug companies and device makers.
The U.S. Food and Drug Administration has cleared an additional facility in Denmark to finish manufacturing monkeypox vaccines, allowing more doses to be distributed and administered across the U.S., Politico tells us. The agency had approved a supplement to the biologics license to allow the Jynneos vaccine to be completed at a Bavarian Nordic plant in Denmark. The company is the official manufacturer of the vaccine, which is cleared to prevent smallpox and monkeypox. Bavarian Nordic had outsourced final manufacturing steps — putting the vaccine into vials — to another facility. Now that the FDA inspection of the plant is complete, Bavarian Nordic can finish production faster.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect